Can-Fite BioPharma (CANF) investor relations material

Company overview and business model

• Advanced clinical-stage biopharmaceutical company developing orally bioavailable small molecule therapeutics for cancer, liver, and inflammatory diseases, leveraging the A3 adenosine receptor (A3AR) as a therapeutic target.

• Pipeline consists of synthetic, highly specific agonists and allosteric modulators targeting A3AR, with a focus on diseases where A3AR is highly expressed in pathological cells.

• Incorporated in Israel since 1994, with principal executive offices in Ramat Gan, Israel.

Financial performance and metrics

• As of December 31, 2025, shareholders' equity was $5.6 million (actual) and $9.4 million (pro forma, post-warrant repricing).

• Total capitalization (long-term liabilities and shareholders' equity) was $6.8 million (actual) and $10.6 million (pro forma).

• 4,285,093 ordinary shares outstanding as of March 30, 2026, with up to 7,579,991 shares outstanding assuming full warrant exercise.

Use of proceeds and capital allocation

• No proceeds from the resale of ADSs by selling shareholders; proceeds from warrant exercises (if not cashless) could total approximately $8.01 million.

• Any proceeds from warrant exercises will be used for research and development, general and administrative expenses, and working capital.

• Pending use, proceeds will be invested in short-term, interest-bearing securities or U.S. government obligations.